Sonpavde Navigates Newfound GU Cancer Treatment Considerations Amid COVID-19 Crisis
In Partnership With:
Guru P. Sonpavde, MD sheds light on how the COVID-19 pandemic has impacted treatment decisions for patients with bladder cancer, perioperative surgical concerns for patients at risk of COVID-19, and the preventative measures Dana-Farber Cancer Institute has put into place to reduce the risk of patients and providers contracting the virus.
Welcome to a very special edition of OncLive® On Air! I'm your host today, Caroline Seymour
OncLive® On Air is a podcast from OncLive, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
But today, we had the pleasure of sitting down with Guru P. Sonpavde, MD, the director of the Bladder Cancer Program and a physician at Dana-Farber Cancer Institute.
In our exclusive interview, Dr. Sonpavde discussed how the COVID-19 pandemic has impacted treatment decisions for patients with bladder cancer, specifically, as they relate to the dosing and scheduling of chemotherapy, immunotherapy, and targeted therapy.
Moreover, Dr. Sonpavde shed light on chemotherapy concerns for patients with muscle invasive and metastatic bladder cancer, perioperative surgical concerns for those at risk of COVID-19, and the preventative measures Dana-Farber Cancer Institute has put into place to reduce the risk of patients and providers contracting the virus.
